Gupta AK, Renaud HJ, Wang T, Cooper EA, Mann A, Polla Ravi S
GLP-1 medications, such as semaglutide (known by brand names like Ozempic or Wegovy), are a class of drugs originally designed to treat type 2 diabetes
The mean baseline body weight was 86 kg, 87.1 kg and 84.6 kg in the placebo, semaglutide tablets7 mg and semaglutide tablets 14 mg arms, respectively
tirzepatide, trial data suggest that such differences may relate to differences in background (placebo) rates in the enrolled trial populations, with the relative increase in many side effects being similar for the two agents (Table 2)
Ninety minutes after drug administration, animals were transcardially perfused using 0.1 M PBS followed by 4% paraformaldehyde (PFA)